Drugs / GSK4524101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06077877 | Oct 2023 → Jun 2026 overdue | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4524101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06077877 ↗ |
| Action | Inhibit | “DNA Polymerase Theta Inhibitor” NCT06077877 ↗ |
| Route | Oral | “Oral DNA Polymerase Theta Inhibitor” NCT06077877 ↗ |